translocates into the nucleus where it modulates target genes in relation to cell proliferation, survival, invasion, angiogenesis and chemoresistance in prostate cancer. 5 STAT3 activation is transient and tightly controlled in normal cells, whereas, constitutively activated STAT3 occurs frequently in a variety of malignant tumours and promotes cancer cell development and progression. 6 Previous studies indicated that IL-6 functions as a paracrine growth factor for androgen-dependent prostate carcinoma LNCaP cells and as an autocrine growth factor for androgen-independent prostate carcinoma DU145 cells. 7 The growth stimulation by IL-6 is accompanied by activation of the STAT3 signalling transduction pathway. 8 Therefore, targeting STAT3 could be a promising therapeutic strategy for treatment of androgen-responsive and androgen-resistant prostate cancers. 3 Artemisia capillaris (AC) is an edible plant. Its young shoots are consumed daily as a vegetable in China and it is regarded as an herbal remedy for various inflammatory diseases such as hepatitis, cholestatic jaundice, and urinary tract infection in Asia. 9 Komiya et al 10 first
recognized the molecular structure of Capillarisin (Cap), an active element extracted from AC, as 2-(p-hdroxyphenoxy)-6-methoxy-5,7-dihy droxychromoneas (C 16 H 12 O 7 ) with strong choleretic activity. Previous studies indicated that Cap has anti-inflammation, anti-oxidation and anti-cancer biological activities. [11] [12] [13] Cap induces apoptosis and cell cycle arrest in osteosarcoma cancer cells. 14 Furthermore, it has been reported to suppress cancer cell invasion via inhibition of NFκB-dependent matrix metallopeptidase (MMP)9 expression in MCF-7 cells and inhibition of the STAT3 signalling cascade in multiple myeloma cell lines. 15, 16 Nevertheless, the functions and effects of Cap in prostate carcinoma cells are still unexplained, and Cap-mediated inhibition of STAT3 activation in the prostate carcinoma cells remains unexplored.
In this study, we determined the effects of Cap on cell proliferation and invasion/migration in prostate carcinoma cells. The inhibitory effect of Cap on constitutive and IL-6-inducible STAT3 activation, which may account for the suppression of migration and invasion of prostate carcinoma cells, was also investigated.
| MATERIALS AND METHODS

| Chemicals
Capillarisin was purchased from Wako (Osaka, Japan), RPMI 1640 media from Life Technologies (Rockville, MD, USA), and recombinant human IL-6
from Peprotech (Rocky Hill, NJ, USA). The 4′ 6-diamidino-2-phenylindole (DAPI) and other chemicals of reagent grade used in this study were obtained from Sigma Chemical (St. Louis, MO, USA).
| Cell cultures
Androgen-independent prostate carcinoma DU145 cells and 
| Flow cytometry
In response to the Cap treatment, cells were serum starved for 24 hours and then cultured in RPMI-1640 medium with 10% FCS and various concentrations of Cap as indicated for another 24 hours. Cell cycle analysis was performed using the FACSCalibur E6147 Cytometer and CELLQuest
Pro Software (BD Biosciences, San Jose, CA, USA); the data were analysed using ModFit LT Mac 3.0 Software, as previously described. 
| Annexin V-FITC apoptosis detection
The cell pellets were harvested after cells were treated with or without Cap for 48 hours. Apoptosis detection and quantification were performed after treatment with Annexin V-FITC (BioVision Inc, Milpitas, CA, USA) and propidium iodide (PI) for 1 hour using the FACSCalibur E6147 Cytometer (BD Biosciences) as previously described. 
| Cell migration assay
For cell migration analysis, a culture insert (ibidi GmbH, Martinsried, Germany) was placed on a culture dish, and DU145 cells were seeded into each reservoir. After 24 hours incubation at 37°C, the insert was removed and the medium was refreshed with the same medium only containing 5% FCS. Then, cells were treated without or with Cap at indicated concentrations for another 24 hours. The wound closure (the gap width) was photographed under an optical microscope with a digital camera. The quantification of cell migration was determined within a defined area using the Image J program (NIH, Bethesda, MD, USA).
| Matrigel invasion assay
The matrigel invasion assay was performed as described previously. Lamin B (M20, Santa Cruz Biotechnology), were detected as internal controls. Antigen-antibody complexes were detected using horseradish peroxide-labelled rabbit anti-mouse immunoglobulin G and an enhanced chemoluminescence detection system (Pierce, Rockford, IL, USA).
| Reporter assay
The reporter vector, pSTAT3-TA-Luc was purchased from Clontech Laboratories, Inc (Mountain View, CA, USA). Cells were plated on 24-well plates at 1 × 10 4 cells per well for 24 hours before transfection. Cells were transiently transfected using TransFast™ transfection reagent with 1 μg per well reporter vector and 0.5 μg per well pCMVSPORT-gal (Invitrogen, Carlsbad, CA, USA), as described previously. 21 Transfected cells were treated with IL-6 and/or Cap as indicated in RPMI 1640 medium with 10% FCS for an additional 24 hours.
Luciferase activity was adjusted for transfection efficiency using the normalization control plasmid pCMVSPORT-gal.
| Statistical analysis
Data were presented as mean ± SE. Statistical significance was determined by Student's t test and one-way ANOVA using the SigmaStat program for Windows, version 2/03 (SPSS Inc, Chicago, IL, USA).
Statistical significance was defined as *P < .05 and **P < .01.
| RESULTS
| Cap inhibits cell growth without induction of cell apoptosis
To explore the anti-proliferative effect of Cap on prostate carcinoma 
| Cap inhibits cell cycle progression in DU145 cells
In the flow cytometric analysis, we found that 100-
Cap induced a 22% increase in G0/G1 arrest together with a decrease in G2/M phase and S phase cells after 48 hours of incubation ( Figure 1D ), confirming retardation of the growth rate by Cap treatment for 48 hours owing to cell cycle arrest.
| Cap inhibits migration and invasion of DU145 cells
To 
| Cap modulates protein expression involving in cell growth and invasion of DU145 cells
Results of the immunoblot assays showed that Cap downregulated cyclin D1, cyclin A, cyclin B, survivin, MMP2 and MMP9 in DU145 cells. However, Cap treatment did not significantly affect the protein expression of cyclin E (Figure 3) . Results of the quantitative analysis are illustrated in Figure 3B ,D,F.
| Cap inhibits cell growth of LNCaP cells via downregulation of cyclin A and cyclin D1 but upregulation of p21 and p27
We observed that Cap inhibited LNCaP cell growth in both dose-and MMP2 were upregulated by IL-6, while Cap reversed the effects of IL-6 ( Figure 5E) . Results of the quantitative analysis are shown in Figure 5F .
| Cap inhibits IL-6-inducible phospho-STAT3 in prostate carcinoma LNCaP cells
Results 
| DISCUSSION
Prostate cancer is one of the most frequently diagnosed malignancies and the leading cause of cancer-related deaths in men worldwide. 1, 22 In this study, we demonstrated that Cap suppressed cell growth without inducing apoptosis in androgen-independent DU145 cells since the Cap did not significantly induce poly (ADPribose) polymerase (PARP) cleavage form, an apoptotic marker, which is similar to a previous study in androgen-dependent LNCaP cells. 19 Moreover, the Cap-inhibited cell growth of prostate carcinoma cells was due to its induction of cell cycle arrest at the G0/G1 phase ( Figures 1 and 4) . These results were consistent with other studies in human breast carcinoma cells, MCF7, osteosarcoma and B-lymphoblast cells, although some of them showed cell apoptosis was induced with higher Cap concentrations. [14] [15] [16] The EC50 between DU145 and LNCaP after Cap treatments for 48 and 72 hours has shown no significant differences; however, recent study revealed that Cap blocks androgen activation on AR-mediated prostate specific antigen expression in LNCaP cells. 19 Whether Cap has the same effect on prostate normal epithelial cells still needs further investigations. Our report is the first study to discover the potential mechanisms of Cap on the anti-proliferative effects of both androgen-dependent and -independent prostate carcinoma cells.
Prior study showed that downregulation of cyclin D1 and cyclin A but upregulation cyclin E, p21 and p27 induced G1 cell cycle arrest in prostate carcinoma cells. 23 Therefore, to explore the potential mechanisms of Cap on cell proliferation, we determined the protein expressions of cyclin D1, cyclin A, cyclin B, cyclin E, p21 and p27 after DU145 or LNCaP cells were treated with Cap. Our immunoblot assays
showed that Cap downregulated cyclin D1, cyclin A and cyclin B, but not cyclin E in DU145 cells ( Figure 3 ). These results were in agreement with a previous study which indicated that Cap induced expression of cyclin D1 in human multiple myeloma U266 cells. 16 Our study found that Cap treatment not only downregulated cyclin D1 but also upregulated p21 and p27 protein expression in LNCaP cells (Figure 4 ). Study has indicated that down modulations of both p21 and p27 enhance the aggressive type of prostate carcinoma cells in vitro and in vivo. 24 Our results demonstrated that Cap enhanced protein expression of p21 and p27, suggesting that Cap is an effective agent in the prevention of prostate cancer.
We continued to verify whether Cap has effects against the migration and invasion of prostate carcinoma DU145 cells. As shown in (Figure 2 ). Our immunoblot assays showed that Cap downregulated protein levels of survivin, a potential mediator of prostate cancer metastasis ( Figure 3C ). Survivin was found to be overexpressed in prostate cancer tissues in vivo. Ectopic overexpression of survivin in prostate carcinoma cells upregulated cell invasion in vitro. 25 Another study in U266 cells also found that Cap downregulated survivin expression. 16 Immunoblot assays in this study indicated that Cap downregulated protein expression of MMP-2 and MMP-9, which may account for the inhibition of migration and invasion (Figure 3 ). MMP-2 and MMP-9 are well-known promoters of invasion in prostate cancer, 26 and blocking of MMP-2 and MMP-9 downregulated cell migration and invasion in prostate carcinoma cells. 27 These results are in agreement with other studies which suggested that Cap blocks MMP-9 expression to decrease the invasion of U266 and MCF7 cells. 15, 16 Interestingly, our results demonstrated that Cap not only downregulated protein expression of MMP-2 and MMP-9 but also blocked the activation of IL-6 on MMP-2 and MMP-9 expression in androgen-resistant DU145 cells with constitutively activated STAT3 ( Figure 5 ).
Interlukin-6 is a multifunctional cytokine known to activate STAT3 and participates in the malignant progression of prostate cancer. 28 Results from our previous in vitro studies have shown that both IL-6 and IL-6 receptor are expressed in DU145 cells, and IL-6 enhances the expression of prostate-specific antigen in LNCaP cells. 29, 30 These results are consistent with early studies indicating that IL-6 functions as a paracrine growth factor for androgen-dependent prostate carcinoma LNCaP cells and as an autocrine growth factor for androgen-independent prostate carcinoma DU145 cells. 7 As shown in Figure therefore, the IL-6/STAT3 signal pathway is considered promising in targeted therapy for hormone-resistant prostate cancer. 31 In this study we demonstrated that Cap inhibits the constitutive and inducible phosphor-activation of STAT3 in prostate carcinoma DU145 cells.
Increased STAT3 activation by IL-6 as an autocrine growth factor is also considered a potential mechanism to enhance androgen receptor reactivation in a ligand-independent manner after androgen deprivation, and thereby promote transition of androgen-sensitive prostate cancer to castration-resistant status. 5 Here, we showed that Cap apparently inhib- Our results demonstrated that Cap upregulated p21 and p27 but downregulated cyclin D1, cyclin A, cyclin B, survivin, MMP2 and MMP9 expression concomitant with suppression of growth, migration, and invasion in androgen-dependent and androgen-independent prostate carcinoma cells. Cap also inhibits constitutive and inducible STAT3 activation. These findings provide evidence suggesting that Cap has potential as an agent in treating prostate cancer with constitutive or IL-6-inducible STAT3 activation.
